ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2025 ANS Winter Conference & Expo
November 9–12, 2025
Washington, DC|Washington Hilton
Standards Program
The Standards Committee is responsible for the development and maintenance of voluntary consensus standards that address the design, analysis, and operation of components, systems, and facilities related to the application of nuclear science and technology. Find out What’s New, check out the Standards Store, or Get Involved today!
Latest Magazine Issues
Sep 2025
Jan 2025
Latest Journal Issues
Nuclear Science and Engineering
October 2025
Nuclear Technology
September 2025
Fusion Science and Technology
Latest News
U.K., Japan to extend decommissioning partnership
The U.K.’s Sellafield Ltd. and Japan’s Tokyo Electric Power Company have pledge to continue to work together for up to an additional 10 years, extending a cooperative agreement begun in 2014 following the 2011 tsunami that resulted in the irreparable damage of TEPCO’s Fukushima Daiichi plant.
Victor R. Prybutok, Leonard M. Gold
Nuclear Technology | Volume 78 | Number 3 | September 1987 | Pages 303-311
Nuclear Power Plant Kalkar (SNR-300) | Nuclear Safety | doi.org/10.13182/NT87-A15996
Articles are hosted by Taylor and Francis Online.
The leukemia incidence risk for a single coal plant, a single nuclear plant, and a single nuclear accident is used to compute the total industry leukemia incidence risk. In the absence of a nuclear power plant accident, the leukemia incidence risk is normally lower for a nuclear industry than for a coal industry of equivalent size. The nuclear industry risk with accidents was compared to the coal industry risk for six proposed dose response curves. Simplifying assumptions about the negligible effect of the cell-killing term and the linear nature of the linear quadratic curve allowed derivation of risk models for the assumption of both linear and quadratic dose response. These derived models, representing leukemia incidence risk bounds, are used to estimate the total industry risk comparison. Evaluation of an accident’s impact on the leukemia incidence risk comparison is done with the risk bounds and compared to the risk evaluations calculated during all six dose response curves. The overlapping plot of the number of nuclear accidents required for equivalent industry environmental risks versus the accident fraction allows the conservative function to be defined.